NEW YORK – Oncocyte said Thursday that it has entered a distribution agreement with CORE Diagnostics to expand the commercial availability of its DetermaRx test to India, the Middle East, and Africa.
DetermaRx is Oncocyte’s first commercially launched assay and was initially called the Razor Genomic test when Oncocyte acquired Razor and it's IP last year.
The test differentiates patients at high risk for lung cancer recurrence who may benefit from adjuvant chemotherapy post-surgery, from those at a lower risk who might avoid it. Oncocyte launched the test in the United States through an early access program this January with two sites. According to the firm, it has since continued to gain traction, rapidly expanding to 18 sites in just the first three months of launch.
Under the terms of the new international agreement with CORE, tissue samples needed for the test will be run in the US by Oncocyte, while CORE Diagnostics will generate test orders and provide customer service to patients in India, the Middle East, and Africa.
Financial terms were not disclosed.
"As we think about expanding beyond the US, one of our strategies is to partner with labs focused on delivering high value, proprietary diagnostics into an existing oncology channel to generate demand and brand awareness," Oncocyte CEO Ron Andrews said in a statement. "We believe CORE's oncology sales force … and customer base … will be critical as we work to increase awareness and availability of our tests among physicians and patients globally."
"As we continue to grow, we intend to extend this distribution model to other geographies including South America and other parts of Asia as well," he added.